A longitudinal study published in PubMed examines neurological disease progression in adults with ataxia telangiectasia. The findings contribute to understanding the disease's impact on adult patients over time.

A phase 3 trial investigates the neurological effects of encapsulated dexamethasone sodium phosphate in children aged 6-9 with ataxia telangiectasia. This multicenter, randomized, double-blind study aims to provide insights into treatment efficacy for this rare condition.

The Ataxia Global Initiative's MRI Biomarkers Working Group has published recommendations for MRI end-points in clinical trials for ataxias. These guidelines aim to standardize the use of MRI as a biomarker in research, potentially enhancing the development of therapies for these conditions.

Rare Disease Day 2026 highlights the ongoing struggles of families facing undiagnosed conditions, including hydrocephalus and Dandy-Walker syndrome. The event emphasizes the need for awareness and support for those dealing with complex health challenges.